Alnylam Pharmaceuticals, Inc.
ALNY
$473.29
$8.361.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 478.84% | -15.31% | 31.38% | 24.92% | -560.61% |
| Total Depreciation and Amortization | -1.01% | -3.20% | 170.11% | -246.95% | -6.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 69.81% | 10.00% | 69.10% | -16.37% | -39.00% |
| Change in Net Operating Assets | -508.69% | 123.07% | -192.47% | -280.91% | 206.96% |
| Cash from Operations | 111.48% | 229.93% | -24.99% | -316.58% | -64.80% |
| Capital Expenditure | 15.05% | -59.34% | 1.36% | -116.94% | 47.72% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 503.85% | -203.54% | 380.12% | -68.15% | -162.10% |
| Cash from Investing | 454.44% | -224.27% | 315.02% | -74.91% | -189.13% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -4.29% | 64.53% | 36.07% | -66.42% | -18.63% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -16.79% | -420.07% | 0.00% | 0.00% | -311.93% |
| Cash from Financing | -934.03% | 21.94% | 42.22% | -69.83% | -21.86% |
| Foreign Exchange rate Adjustments | -103.37% | 95.66% | 181.40% | -214.43% | 583.75% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 302.66% | 74.66% | 140.04% | -201.94% | -54.17% |